Q4 2016

Filed Mar 13, 2017 · 10-K · 72 days after period end · 0001104659-17-016024

Q4 2016 · 10-K

derived · Computed from the longer spans the company filed.

Revenue

$8.54M

derivedno prior Q4 2015 on file

Net Income

-$15.41M

derivedno prior Q4 2015 on file

EPS, diluted—

Same quarter

no prior Q4 2015 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2016 · filed Mar 13, 2017 · 72 d after period end

Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR